Immune check-point inhibition is dramatically improving patient outcomes in diverse cancers, many of which responded poorly to traditional cytotoxic agents. Drivers of heterogeneous response to immune check-point therapy are poorly characterized. Cachectic cancer patients exhibit elevated pembrolizumab clearance and poor response highlighting the immense therapeutic challenge posed by cancer cachexia.
https://ift.tt/2JwtJeF
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.